we can see how our therapeutics work in different populations, helping us to advance our pipeline to meet unmet needs in patients worldwide,” said Xueming Qian, founder, chair and CEO of Transcenta.

US stocks pulled back on Tuesday, led by a nearly 2% decline in the Nasdaq, following two days of gains as investors ...

IBT is expertly designed and staffed with a collective 150+ years of experience in early-stage research supporting therapeutics and ... Michael Wilhelm, CEO of LNS, stated: “We are excited ...

Courtesy of Stoke Therapeutics Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO. Dr. Edward Kaye is stepping down from the position Wednesday ...

Ms. Collins will also serve as interim CEO. Dr. Khandros will remain on Nutcracker Therapeutics’ board of directors. Dr. Khandros co-founded Nutcracker Therapeutics in 2018, alongside Chief ...

Akari Therapeutics (AKTX) announced the appointment of Abizer Gaslightwala as President and Chief Executive Officer, CEO, effective April 21, ...

Stoke Therapeutics (STOK) announced that Edward Kaye has decided to step down from his role as CEO effective as of March 19. To facilitate a smooth transition, Kaye will serve as an advisor to the ...

(RTTNews) - Biotechnology company Stoke Therapeutics, Inc. (STOK) announced Tuesday that Edward Kaye has decided to step down from his role as Chief Executive Officer effective as of March 19, 2025.

Stoke Therapeutics, Inc. (NASDAQ ... Smith, a current Director, will take over as Interim CEO, while Arthur Tzianabos, Ph.D., assumes the position of Interim Executive Chairman to oversee the ...